Issue link: https://beckershealthcare.uberflip.com/i/1510256
FASENRA® (benralizumab) Subcutaneous Injection 30 mg Please see additional Important Safety Information throughout and Brief Summary of full Prescribing Information on adjacent pages. IMPACT IN ASTHMA EXACERBATION-RELATED HRU AND MEDICAL COSTS 4 SUMMARY 3,4 In this real-world analysis, patients treated with benralizumab experienced an observed reduction in asthma exacerbations across eosinophil blood levels, following initiation of benralizumab. In those who switched from mepolizumab or omalizumab to benralizumab in the post index period, reductions were observed in asthma exacerbations There was an observed reduction in asthma exacerbation-related HRU and medical costs with benralizumab These fi ndings are consistent with previous clinical trials and observational studies, strengthening the body of evidence supporting the eff ectiveness of benralizumab in severe eosinophilic asthma (n=1292) Primary Cohort Observed reduction in asthma exacerbation-related healthcare resource utilization per person-year of up to 58% and associated medical costs by nearly 50%. IMPORTANT SAFETY INFORMATION (cont'd) ADVERSE REACTIONS The most common adverse reactions (incidence ≥ 5%) include headache and pharyngitis. Injection site reactions (eg, pain, erythema, pruritus, papule) occurred at a rate of 2.2% in patients treated with FASENRA compared with 1.9% in patients treated with placebo. USE IN SPECIFIC POPULATIONS A pregnancy exposure registry monitors pregnancy outcomes in women exposed to FASENRA during pregnancy. To enroll call 1-877-311-8972 or visit www.mothertobaby.org/fasenra. The data on pregnancy exposure from the clinical trials are insuffi cient to inform on drug-associated risk. Monoclonal antibodies such as benralizumab are transported across the placenta during the third trimester of pregnancy; therefore, potential eff ects on a fetus are likely to be greater during the third trimester of pregnancy. SCAN FOR ADDITIONAL STUDIES ON SEVERE EOSINOPHILIC ASTHMA 12 months pre-index 12 months post-index ED = emergency department; HRU = healthcare resource utilization; IP = inpatient; N = number; OP = outpatient; SD = standard deviation * Medical costs were estimated from charges using a charge-to-cost ratio of 0.2575 calculated from HCUP 2018 national hospital inpatient median charges and median costs. (Source: HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD.) 12-months pre-index $3,572 ± $11,255 $805 ± $2,147 $314 ± $330 12-months post-index $1,745 ± $8,527 $383 ± $1,528 $161 ± $357 Percent reduction 51% 52% 49% Medical cost, * mean ±SD IP stays ED visits OP visits Rate of asthma exacerbation- related HRU per person-year 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 54 % 58 % 0.51 0.65 3.03 0.21 0.30 1.28 54 % 58 % 54 % 58 % This is an observational study; clinical implications cannot be determined from this payer database study. 58 % 50 % US-79385_US-51016 Fasenra Beckers Hospital Review Advertorial.indd 3 US-79385_US-51016 Fasenra Beckers Hospital Review Advertorial.indd 3 9/13/23 9:57 AM 9/13/23 9:57 AM